Could J&J Trip up the Merck and Schering-Plough Deal?

By Taskin Ahmed

Pharma Deals Review: Vol 2009 Issue 3 (Table of Contents)

Published: 13 Mar-2009

DOI: 10.3833/pdr.v2009.i3.1076     ISSN: 1756-7874

Section: Mergers & Acquisitions

Fulltext:

Abstract

The change of ownership clause in the contract between Johnson & Johnson (J&J) and Schering-Plough over the control of two key products, Remicade® and golimumab, could be a stumbling block in the merger between Merck and Schering-Plough...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details